Heat shock proteins (HSPs) and chaperones are highly conserved stress-induced factors. They regulate not only protein folding and stability but are also actively involved in protein transport and transcriptional regulation. HSPs have cytoprotective roles and are essential for cancer
cell survival. Noteworthy, HSPs are often upregulated in cancer. Therefore, HSPs emerged as drug targets for cancer therapy. Especially for prostate cancer (PCa) therapy, a battery of different compounds has been identified that act with different modes to inhibit PCa growth. The androgen
receptor (AR) is a major player in PCa progression and is a well-known interacting factor of HSPs. Since the AR function is very dependent on HSP activity, many emerging compounds address the AR-associated HSPs as novel drug targets. Here, we provide an insight into the different classes of
HSPs, their association with the human AR, the role of HSPs in human PCa development and review also the targeting of HSPs in human PCa. Further, the function and the underlying molecular mechanisms of specific compounds that are currently under investigation for the use against PCa growth
will be comprehensively summarized.
Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.